Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005. Implications for biological regulation of 5-lipoxygenase

Adv Prostaglandin Thromboxane Leukot Res. 1994:22:23-31.

Authors

A Hatzelmann¹, R Fruchtmann, K H Mohrs, S Raddatz, M Matzke, U Pleiss, J Keldenich, R Müller-Peddinghaus

Affiliation

¹ Institute for Cardiovascular and Arteriosclerosis Research, Bayer AG, Wuppertal, Germany.

PMID: 7771337

No abstract available

Publication types

Review

MeSH terms

5-Lipoxygenase-Activating Proteins
Arachidonate 5-Lipoxygenase / metabolism
Binding, Competitive
Carrier Proteins / antagonists & inhibitors*
Carrier Proteins / metabolism
Humans
Lipoxygenase Inhibitors*
Membrane Proteins / antagonists & inhibitors*
Membrane Proteins / metabolism
Quinolines / chemistry
Quinolines / pharmacology*

Substances

5-Lipoxygenase-Activating Proteins
ALOX5AP protein, human
Carrier Proteins
Lipoxygenase Inhibitors
Membrane Proteins
Quinolines
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid
Arachidonate 5-Lipoxygenase